Todd Hembrough

4.5k total citations
71 papers, 2.3k citations indexed

About

Todd Hembrough is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Todd Hembrough has authored 71 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 25 papers in Cancer Research and 24 papers in Molecular Biology. Recurrent topics in Todd Hembrough's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Cancer Genomics and Diagnostics (16 papers) and HER2/EGFR in Cancer Research (9 papers). Todd Hembrough is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Cancer Genomics and Diagnostics (16 papers) and HER2/EGFR in Cancer Research (9 papers). Todd Hembrough collaborates with scholars based in United States, Spain and United Kingdom. Todd Hembrough's co-authors include Steven L. Gonias, Franco Cecchi, Li Li, Shawn J. Green, Adonia E. Papathanassiu, Glenn M. Swartz, Victor S. Pribluda, William R. Ferrell, John C. Lockhart and Lynette Dunning and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Todd Hembrough

66 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Todd Hembrough United States 25 942 880 653 524 398 71 2.3k
Tobias Dechow Germany 24 692 0.7× 793 0.9× 318 0.5× 475 0.9× 275 0.7× 73 2.0k
Rajesh R. Singh United States 29 1.4k 1.5× 693 0.8× 1.2k 1.8× 551 1.1× 391 1.0× 48 2.7k
Cristina E. Tognon United States 26 2.0k 2.1× 980 1.1× 705 1.1× 509 1.0× 691 1.7× 81 3.6k
Raushan T. Kurmasheva United States 27 1.3k 1.4× 814 0.9× 366 0.6× 546 1.0× 196 0.5× 120 2.3k
Céline Callens France 27 1.0k 1.1× 670 0.8× 740 1.1× 480 0.9× 197 0.5× 83 2.2k
Sílvia Menéndez United States 32 2.5k 2.7× 1.2k 1.3× 903 1.4× 532 1.0× 430 1.1× 76 4.0k
Karin D. Berg United States 18 931 1.0× 730 0.8× 456 0.7× 232 0.4× 635 1.6× 29 2.2k
Gerwin Heller Austria 25 1.2k 1.3× 583 0.7× 485 0.7× 308 0.6× 266 0.7× 77 2.0k
Luciano Cascione Switzerland 28 1.6k 1.7× 631 0.7× 1.0k 1.5× 340 0.6× 257 0.6× 131 2.7k
Yutaka Kawakami Japan 22 777 0.8× 915 1.0× 305 0.5× 409 0.8× 228 0.6× 37 2.4k

Countries citing papers authored by Todd Hembrough

Since Specialization
Citations

This map shows the geographic impact of Todd Hembrough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Hembrough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Hembrough more than expected).

Fields of papers citing papers by Todd Hembrough

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Hembrough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Hembrough. The network helps show where Todd Hembrough may publish in the future.

Co-authorship network of co-authors of Todd Hembrough

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Hembrough. A scholar is included among the top collaborators of Todd Hembrough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Hembrough. Todd Hembrough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schwarzer, Adrian, Matheus Oliveira, Mark Hannink, et al.. (2023). Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. Molecular Cancer Therapeutics. 22(11). 1290–1303. 6 indexed citations
2.
Zhang, Qu, Jia Luo, Song Wu, et al.. (2020). Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery. 10(12). 1842–1853. 221 indexed citations
3.
Cecchi, Francesca, Sainetra Sridhar, Melissa de los Reyes, et al.. (2020). 13P HER2 low testing in breast cancer: How to optimize detection. Annals of Oncology. 31. S21–S21. 3 indexed citations
4.
Serna, Garazi, Franco Cecchi, Roberta Fasani, et al.. (2019). Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9(1). 13568–13568. 11 indexed citations
5.
Schaff, Lauren, Dongyao Yan, Sheeno Thyparambil, et al.. (2019). Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Journal of Neuro-Oncology. 146(1). 163–170. 26 indexed citations
6.
Maron, Steven B., Lindsay Alpert, Heewon Kwak, et al.. (2018). Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery. 8(6). 696–713. 79 indexed citations
7.
Park, Jong Chul, Ting Martin, Lisa M. Rooper, et al.. (2018). Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor‐2 high expressing salivary duct carcinomas. Head & Neck. 40(12). E100–E106. 21 indexed citations
8.
Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.
9.
Offin, Michael, Todd Hembrough, Franco Cecchi, et al.. (2018). P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial. Journal of Thoracic Oncology. 13(10). S599–S599. 4 indexed citations
10.
Thyparambil, Sheeno, Yeoun Jin Kim, Andrew G. Chambers, et al.. (2018). Abstract 778: Potential drug targets for adenoid cystic carcinoma elucidated by proteogenomic analysis. Cancer Research. 78(13_Supplement). 778–778. 2 indexed citations
11.
Schwartz, Sarit, Franco Cecchi, Yuan Tian, et al.. (2017). Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Annals of Oncology. 28. iii95–iii95. 3 indexed citations
12.
An, Eunkyung, Chan‐Young Ock, T.-Y. Kim, et al.. (2016). Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Annals of Oncology. 28(1). 110–115. 32 indexed citations
13.
Blackler, Adele, Wei‐Li Liao, Emily O’Day, et al.. (2016). Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. Journal of the National Comprehensive Cancer Network. 14(5). 503–507. 7 indexed citations
14.
Toki, Maria, Franco Cecchi, Todd Hembrough, Konstantinos Syrigos, & David L. Rimm. (2016). PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 11(11). S287–S287. 1 indexed citations
15.
16.
Catenacci, Daniel V.T., Wei‐Li Liao, Sheeno Thyparambil, et al.. (2014). Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE. 9(7). e100586–e100586. 40 indexed citations
17.
Hembrough, Todd, Les Henderson, Wei‐Li Liao, et al.. (2014). Quantification of HER2 from gastroesophageal cancer (GEC) FFPE tissue by mass spectrometry (MS).. Journal of Clinical Oncology. 32(3_suppl). 17–17. 1 indexed citations
18.
Nucíforo, Paolo, Sheeno Thyparambil, Ana C. Garrido-Castro, et al.. (2014). Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. Journal of Clinical Oncology. 32(15_suppl). 649–649. 1 indexed citations
19.
Hembrough, Todd, Sheeno Thyparambil, Wei-Li Liao, et al.. (2013). Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue. Journal of Molecular Diagnostics. 15(4). 454–465. 48 indexed citations
20.
Fletcher, Graham C., Richard D. Brokx, Todd Hembrough, et al.. (2010). ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action. Molecular Cancer Therapeutics. 10(1). 126–137. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias Dechow Breakdown of academic impact, for papers by Rajesh R. Singh Breakdown of academic impact, for papers by Cristina E. Tognon Breakdown of academic impact, for papers by Raushan T. Kurmasheva Breakdown of academic impact, for papers by Céline Callens Breakdown of academic impact, for papers by Sílvia Menéndez Breakdown of academic impact, for papers by Karin D. Berg Breakdown of academic impact, for papers by Gerwin Heller Breakdown of academic impact, for papers by Luciano Cascione Breakdown of academic impact, for papers by Yutaka Kawakami
Rankless by CCL
2026